Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma

ClinicalTrials.gov ID: NCT02462525

Public ClinicalTrials.gov record NCT02462525. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 17, 2026, 12:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a Phase 1/1b, open-label, dose-escalation study designed to evaluate the safety, pharmacokinetics, and to determine the recommended Phase 2 dose of ABBV-838 in subjects with relapsed and refractory multiple myeloma.

Study identification

NCT ID: NCT02462525
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 1
Lead sponsor: AbbVie; Industry
Enrollment: 74 participants

Conditions and interventions

Conditions

Multiple Myeloma

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years to 99 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 5, 2015
Primary completion: Dec 5, 2017
Completion: Dec 5, 2017
Last update posted: Sep 12, 2018

2015 – 2017

United States locations

U.S. sites: 5
U.S. states: 5
U.S. cities: 5

Facility	City	State	ZIP	Site status
The University of Chicago Medical Center /ID# 139403	Chicago	Illinois	60637	—
University of Michigan Medical Center /ID# 139402	Ann Arbor	Michigan	48109	—
Washington University School of Medicine /ID# 135708	St Louis	Missouri	63110-1093	—
Mount Sinai Medical Center /ID# 133569	New York	New York	10029	—
The Sarah Cannon Research Institute /ID# 135814	Nashville	Tennessee	37203	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 14 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02462525, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 12, 2018 · Synced Sep 17, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02462525 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →